S&P 500   4,299.70 (+0.59%)
DOW   33,666.34 (+0.35%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.75%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.37%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.58%)
GE   112.34 (+1.31%)
DIS   80.13 (+0.29%)
AMC   7.79 (+2.91%)
PFE   32.09 (-0.03%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
S&P 500   4,299.70 (+0.59%)
DOW   33,666.34 (+0.35%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.75%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.37%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.58%)
GE   112.34 (+1.31%)
DIS   80.13 (+0.29%)
AMC   7.79 (+2.91%)
PFE   32.09 (-0.03%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
S&P 500   4,299.70 (+0.59%)
DOW   33,666.34 (+0.35%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.75%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.37%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.58%)
GE   112.34 (+1.31%)
DIS   80.13 (+0.29%)
AMC   7.79 (+2.91%)
PFE   32.09 (-0.03%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
S&P 500   4,299.70 (+0.59%)
DOW   33,666.34 (+0.35%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.75%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.37%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.58%)
GE   112.34 (+1.31%)
DIS   80.13 (+0.29%)
AMC   7.79 (+2.91%)
PFE   32.09 (-0.03%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
NASDAQ:INCY

Incyte (INCY) Stock Forecast, Price & News

$58.61
-0.50 (-0.85%)
(As of 05:37 PM ET)
Compare
Today's Range
$58.44
$59.33
50-Day Range
$58.10
$65.93
52-Week Range
$57.90
$86.29
Volume
795,163 shs
Average Volume
1.76 million shs
Market Capitalization
$13.13 billion
P/E Ratio
35.96
Dividend Yield
N/A
Price Target
$82.00

Incyte MarketRank™ Forecast

Analyst Rating
Hold
2.39 Rating Score
Upside/​Downside
39.5% Upside
$82.00 Price Target
Short Interest
Bearish
2.89% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-2.45
Upright™ Environmental Score
News Sentiment
0.50mentions of Incyte in the last 14 days
Based on 13 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
33.22%
From $2.98 to $3.97 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.88 out of 5 stars

Medical Sector

52nd out of 975 stocks

Commercial Physical Research Industry

1st out of 14 stocks


INCY stock logo

About Incyte (NASDAQ:INCY) Stock

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States, Europe, Japan, and internationally. The company offers JAKAFI (ruxolitinib), for the treatment of adults with intermediate or high-risk myelofibrosis; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include axatilimab, an anti-CSF-1R monoclonal antibody being developed as a therapy for patients with chronic GVHD as well as in additional immune-mediated diseases; and parsaclisib, a PI3Kd inhibitor which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. It also develops retifanlimab, is in Phase III clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer, and Fast Track designation for the treatment of metastatic MSI-H or DNA mismatch repair (dMMR) endometrial cancer; and INCB99280 and INCB99318 currently under Phase I for the treatment solid tumors. It has collaboration out- license agreements with Novartis, Lilly, Innovent, InnoCare, Maruho, and CMS Aesthetics Limited; and in- license agreements with Agenus, Merus, MacroGenics, Syros, MorphoSys, and Syndax. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

INCY Price History

INCY Stock News Headlines

Argenx's 28% Surge & Promising Product Propel Investor Confidence (INCY)
Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.
U.S. drive to onshore battery supply chains could create big winners in lithium
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Incyte Co. (NASDAQ:INCY) Receives $82.00 Consensus PT from Analysts
Truist Financial Reiterates Buy Rating for Incyte (NASDAQ:INCY)
StockNews.com Upgrades Incyte (NASDAQ:INCY) to Strong-Buy
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Incyte teams with Mia Hamm to raise GvHD awareness
JMP Securities Reaffirms Their Buy Rating on Incyte (INCY)
Incyte Corporation Q2 Profit Increases, beats estimates
Incyte Q2 Profit, Revenue Up, Above Estimates
See More Headlines
Receive INCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Incyte and its competitors with MarketBeat's FREE daily newsletter.

INCY Company Calendar

Last Earnings
8/01/2023
Today
9/28/2023
Next Earnings (Estimated)
11/07/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:INCY
CUSIP
45337C10
Employees
2,324
Year Founded
1991

Price Target and Rating

Average Stock Price Forecast
$82.00
High Stock Price Forecast
$100.00
Low Stock Price Forecast
$61.00
Forecasted Upside/Downside
+39.8%
Consensus Rating
Hold
Rating Score (0-4)
2.39
Research Coverage
18 Analysts

Profitability

Net Income
$340.66 million
Pretax Margin
15.90%

Debt

Sales & Book Value

Annual Sales
$3.39 billion
Cash Flow
$2.41 per share
Book Value
$19.64 per share

Miscellaneous

Free Float
184,873,000
Market Cap
$13.14 billion
Optionable
Optionable
Beta
0.69

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Herve HoppenotMr. Herve Hoppenot (Age 63)
    CEO & Chairman
    Comp: $2.89M
  • Ms. Christiana Stamoulis MBA (Age 52)
    Exec. VP & CFO
    Comp: $1.16M
  • Ms. Maria E. Pasquale J.D.Ms. Maria E. Pasquale J.D. (Age 57)
    Exec. VP, Gen. Counsel & Corp. Sec.
    Comp: $1.02M
  • Dr. Barry P. Flannelly M.B.A. (Age 65)
    MBA, Pharm.D., Exec. VP & GM of North America
    Comp: $996.28k
  • Dr. Steven H. Stein M.D. (Age 56)
    Exec. VP & Chief Medical Officer
    Comp: $1.22M
  • Dr. Pablo J. Cagnoni M.D. (Age 60)
    Ph.D., Pres and Head of R&D
  • Mr. Thomas Tray (Age 45)
    VP of Fin., Chief Accounting Officer & Controller
  • Mr. Michael James Morrissey (Age 59)
    Exec. VP & Head of Global Technical Operations
  • Ms. Christine Chiou
    Head of Investor Relations
  • Ms. Pamela M. Murphy (Age 72)
    VP of Investor Relations & Corp. Communications













INCY Stock - Frequently Asked Questions

Should I buy or sell Incyte stock right now?

18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last twelve months. There are currently 1 sell rating, 9 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" INCY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INCY, but not buy additional shares or sell existing shares.
View INCY analyst ratings
or view top-rated stocks.

What is Incyte's stock price forecast for 2023?

18 brokerages have issued 12-month price targets for Incyte's stock. Their INCY share price forecasts range from $61.00 to $100.00. On average, they anticipate the company's share price to reach $82.00 in the next year. This suggests a possible upside of 39.8% from the stock's current price.
View analysts price targets for INCY
or view top-rated stocks among Wall Street analysts.

How have INCY shares performed in 2023?

Incyte's stock was trading at $80.32 at the beginning of the year. Since then, INCY shares have decreased by 27.0% and is now trading at $58.64.
View the best growth stocks for 2023 here
.

Are investors shorting Incyte?

Incyte saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 6,480,000 shares, an increase of 13.5% from the August 31st total of 5,710,000 shares. Based on an average trading volume of 1,580,000 shares, the short-interest ratio is presently 4.1 days.
View Incyte's Short Interest
.

When is Incyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 7th 2023.
View our INCY earnings forecast
.

How were Incyte's earnings last quarter?

Incyte Co. (NASDAQ:INCY) issued its earnings results on Tuesday, August, 1st. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.08. The biopharmaceutical company had revenue of $954.61 million for the quarter, compared to analyst estimates of $920.18 million. Incyte had a trailing twelve-month return on equity of 9.25% and a net margin of 10.43%.

What is Hervé Hoppenot's approval rating as Incyte's CEO?

22 employees have rated Incyte Chief Executive Officer Hervé Hoppenot on Glassdoor.com. Hervé Hoppenot has an approval rating of 80% among the company's employees.

What other stocks do shareholders of Incyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), (KITE) (KITE), Freeport-McMoRan (FCX) and NVIDIA (NVDA).

What is Incyte's stock symbol?

Incyte trades on the NASDAQ under the ticker symbol "INCY."

Who are Incyte's major shareholders?

Incyte's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (10.66%), State Street Corp (4.40%), Renaissance Technologies LLC (2.15%), Geode Capital Management LLC (1.82%), Bellevue Group AG (1.18%) and Northern Trust Corp (0.90%). Insiders that own company stock include Barry P Flannelly, Bros Advisors Lp Baker, Dashyant Dhanak, Herve Hoppenot, Jonathan Elliott Dickinson, Maria E Pasquale, Michael James Morrissey, Paula J Swain, Steven H Stein, Thomas Tray, Vijay K Iyengar, Wendy L Dixon and Yao Wenqing.
View institutional ownership trends
.

How do I buy shares of Incyte?

Shares of INCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Incyte's stock price today?

One share of INCY stock can currently be purchased for approximately $58.64.

How much money does Incyte make?

Incyte (NASDAQ:INCY) has a market capitalization of $13.14 billion and generates $3.39 billion in revenue each year. The biopharmaceutical company earns $340.66 million in net income (profit) each year or $1.63 on an earnings per share basis.

How many employees does Incyte have?

The company employs 2,324 workers across the globe.

How can I contact Incyte?

Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The official website for the company is www.incyte.com. The biopharmaceutical company can be reached via phone at (302) 498-6700, via email at mbooth@incyte.com, or via fax at 302-425-2750.

This page (NASDAQ:INCY) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -